Biogen Idec has filed a biologics license application with the FDA for approval to use its interferon-based drug Plegridy as a treatment for relapsing forms of multiple sclerosis. The application was based on data from a late-stage trial indicating that Plegridy significantly reduced disease activity. Biogen also plans a European application within weeks.
Biogen submits MS drug candidate Plegridy for FDA approval
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan